<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>COMBIVIRÂ - lamivudine and zidovudineÂ tablet, film coatedÂ </strong><br>H.J. Harkins Company, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use COMBIVIR safely and effectively. See full prescribing information for COMBIVIR.<br>Â <br>COMBIVIR (lamivudine and zidovudine) Tablets 150 mg/300 mg<br>Initial U.S. Approval: 1997</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: RISK OF HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<ul>
<li><span class="Bold">Hematologic toxicity including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> have been associated with the use of zidovudine, one of the components of COMBIVIR (5.1)</span></li>
<li><span class="Bold">Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with prolonged use of zidovudine. (5.2)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including zidovudine. Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur. (5.3)</span></li>
<li><span class="Bold">Severe, acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine, a component of COMBIVIR. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. (5.4)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> (5.8) (month year) </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: RISK OF HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<ul>
<li><span class="Bold">Hematologic toxicity including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> have been associated with the use of zidovudine, one of the components of COMBIVIR (5.1)</span></li>
<li><span class="Bold">Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with prolonged use of zidovudine. (5.2)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including zidovudine. Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur. (5.3)</span></li>
<li><span class="Bold">Severe, acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) and have discontinued lamivudine, a component of COMBIVIR. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. (5.4)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">COMBIVIR, a combination of twoÂ nucleoside analogue reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (1)  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Adults and Adolescents weighing â‰¥30Â kg: 1Â tablet twice daily. (2.1)</li>
<li>Pediatrics: Dosage should be based on body weight not to exceed adult doses. (2.2)</li>
<li>COMBIVIR, a fixed-dose product, should not be prescribed for pediatric patients weighing less than 30Â kg or patients requiring dosage adjustment, such as those with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or patients experiencing dose-limiting adverse reactions. (2.3)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: Scored 150 mg lamivudine and 300 mg zidovudine (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">COMBIVIR Tablets are contraindicated in patients with previously demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>). (4)  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>See boxed warning for information about the following: hematologic toxicity, symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, and severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B. (5.1, 5.2, 5.3. 5.4)</li>
<li>COMBIVIR should not be administered with other lamivudine- or zidovudine-containing products or emtricitabine-containing products. (5.5)</li>
<li>Hepatic decompensation, some fatal, has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy and interferon alfa with/without ribavirin. Discontinue COMBIVIR as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both. (5.6)</li>
<li>Exacerbation of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Co-administration of ribavirin and zidovudine is not advised. (5.6)</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>: Use with caution in pediatric patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> or other significant risk factors for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Discontinue treatment as clinically appropriate. (5.7)</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> (5.8) and redistribution/accumulation of body fat (5.9) have been reported in patients treated with combination antiretroviral therapy.</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul><li>Most commonly reported adverse reactions (incidence greater than or equal to 15%) in adult and pediatric HIV-1 clinical studies of combination lamivudine and zidovudine were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, nasal signs and symptoms, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>. (6.1)</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Concomitant use with the following drugs should be avoided: stavudine (7.1), zalcitabine (7.1), doxorubicin (7.2).</li>
<li>Bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine. (7.3)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Physicians are encouraged to register patients in the Antiretroviral Pregnancy Registry by calling 1-800-258-4263. (8.1)</li>
<li>Nursing Mothers: HIV-1 infected mothers in the United States should not breastfeed to avoid potential postnatal transmission of HIV-1. (8.3)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adults and Adolescents Weighing â‰¥30Â kg</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Patients Requiring Dosage Adjustment</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hemotologic Toxicity/Bone Marrow Suppression</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> With Steatosis</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Patients With HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Use With Other, Lamivudine-, Zidovudine-, and/or Emtricitabine-Containing Products</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Use With Interferon- and Ribavirin-Based Regimens</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Fat Redistribution</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Antiretroviral Agents</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Doxorubicin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Hematologic/Bone Marrow Suppressive/Cytotoxic Agents</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Interferon- and Ribavirin-Based Regimens</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Trimethoprim/Sulfamethoxazole (TMP/SMX)</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Reproductive and Developmental Toxicology Studies</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adults</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Prevention of Maternal-Fetal HIV-1 Transmission</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Advice for the Patient</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_b2c19d4f-e837-40e8-9c51-49538ac7ca8d"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: HEMATOLOGIC TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B</span></h1>
<p class="First"><span class="Bold"><span class="Bold">Hematologic Toxicity: Â  </span>Zidovudine, one of the 2 active ingredients in COMBIVIR<span class="Sup">Â®</span> (lamivudine and zidovudine) Tablets, has been associated with hematologic toxicity including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, particularly in patients with advanced HIV-1 disease <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</span></p>
<p><span class="Bold"><span class="Bold"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>: </span>Prolonged use of zidovudine has been associated with symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</span></p>
<p><span class="Bold"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span>: </span><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including lamivudine, zidovudine, and other antiretrovirals. Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</span></p>
<p><span class="Bold"><span class="Bold">Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B: Severe, a</span>cute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who are co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of COMBIVIR. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue COMBIVIR and are co-infected with HIV-1 and HBV. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_9157e013-d737-4490-a3cd-66413bbc0270"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">COMBIVIR, a combination of twoÂ nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_d00470dd-e50c-4159-82b8-758afbeabd0a"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_325f6e97-1ea6-428b-900a-efe3a37396f3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adults and Adolescents Weighing â‰¥30Â kg</h2>
<p class="First">The recommended oral dose of COMBIVIR in HIV-1-infected adults and adolescents weighing greater than or equal to 30Â kg is 1Â tablet (containing 150Â mg of lamivudine and 300Â mg of zidovudine) twice daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5ed9f689-eca7-488d-a420-1f62459ef18b"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Patients</h2>
<p class="First">The recommended oral dosage of scored COMBIVIR Tablets for pediatric patients who weigh greater than or equal to 30Â kg and for whom a solid oral dosage form is appropriate is 1Â tablet administered twice daily.</p>
<p>Before prescribing COMBIVIR Tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow a COMBIVIR tablet, the liquid oral formulations should be prescribed: EPIVIR<span class="Sup">Â®</span> (lamivudine) Oral Solution and RETROVIR<span class="Sup">Â®</span>Â (zidovudine) Syrup.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1dd7e435-d212-417e-891e-44da47f94ec6"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Patients Requiring Dosage Adjustment</h2>
<p class="First">Because COMBIVIR is a fixed-dose combination tablet, it should not be prescribed for pediatric patients weighing less than 30Â kg or patients requiring dosage adjustment, such as those with reduced renal function (creatinine clearance less than 50Â mL/min), patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or patients experiencing dose-limiting adverse reactions. Liquid and solid oral formulations of the individual components of COMBIVIR are available for these populations.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_d55d40f0-3e6f-48dc-8420-6f8a608f8d26"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">COMBIVIR Tablets contain 150Â mg of lamivudine and 300Â mg of zidovudine. The tablets are white, scored, film-coated, modified capsule-shaped tablets, debossed on both tablet faces, such that when broken in half, the full â€œGX FC3â€? code is present on both halves of the tablet (â€œGXâ€? on one face and â€œFC3â€? on the opposite face of the tablet).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_f74d4c49-160b-417a-b916-e57da6d0db06"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">COMBIVIR Tablets are contraindicated in patients with previously demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) to any of the components of the product.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_5080500e-260e-49e3-86f7-55f32f2d4d04"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b6cfca6e-aa19-4db8-ae0a-b5e07276076d"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Hemotologic Toxicity/Bone Marrow Suppression</h2>
<p class="First">Zidovudine, a component of COMBIVIR, has been associated with hematologic toxicity including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, particularly in patients with advanced HIV-1 disease. COMBIVIR should be used with caution in patients who have bone marrow compromise evidenced by granulocyte count less than 1,000Â cells/mm<span class="Sup">3</span> or hemoglobin less than 9.5Â g/dL <span class="Italics">[see Adverse Reactions (6.1)]</span>.</p>
<p>Frequent blood counts are strongly recommended in patients with advanced HIV-1 disease who are treated with COMBIVIR. Periodic blood counts are recommended for other HIV-1-infected patients. If <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> develops, dosage interruption may be needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b1e1af2a-e6bd-48f0-93b1-61396946c166"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, with pathological changes similar to that produced by HIV-1 disease, have been associated with prolonged use of zidovudine, and therefore may occur with therapy with COMBIVIR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7e5c0654-bc8b-4fa7-83e6-bbfc083dbe82"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> With Steatosis</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including lamivudine, zidovudine, and other antiretrovirals. A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged nucleoside exposure may be risk factors. Particular caution should be exercised when administering COMBIVIR to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with COMBIVIR should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8cc751f4-8be6-4bdb-ac20-789ae4b7ac25"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Patients With HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></h2>
<p class="First"><span class="Underline">Posttreatment Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>:</span> In clinical trials in non-HIV-1-infected patients treated with lamivudine for chronic HBV, clinical and laboratory evidence of exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have occurred after discontinuation of lamivudine. These exacerbations have been detected primarily by serum ALT elevations in addition to re-emergence of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B viral DNA (HBV DNA). Although most events appear to have been self-limited, fatalities have been reported in some cases. Similar events have been reported from post-marketing experience after changes from lamivudine-containing HIV-1 treatment regimens to non-lamivudine-containing regimens in patients infected with both HIV-1 and HBV. The causal relationship to discontinuation of lamivudine treatment is unknown. Patients should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. There is insufficient evidence to determine whether re-initiation of lamivudine alters the course of posttreatment exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p><span class="Underline">Important Differences Among Lamivudine-Containing Products:</span> COMBIVIR Tablets contain a higher dose of the same active ingredient (lamivudine) than EPIVIR-HBV<span class="Sup">Â® </span>(lamivudine) Tablets and Oral Solution. EPIVIR-HBV was developed for treating <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B. Safety and efficacy of lamivudine have not been established for treatment of chronic hepatitisÂ B in patients co-infected with HIV-1 and HBV.</p>
<p><span class="Underline">Emergence of Lamivudine-Resistant HBV:</span> In non-HIV-infected patients treated with lamivudine for chronic hepatitisÂ B, emergence of lamivudine-resistant HBV has been detected and has been associated with diminished treatment response (see full prescribing information for EPIVIR-HBV for additional information). Emergence of hepatitisÂ B virus variants associated with resistance to lamivudine has also been reported in HIV-1-infected patients who have received lamivudine-containing antiretroviral regimens in the presence of concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with hepatitisÂ B virus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_00fd8103-7fa3-4ef1-929d-9d3f60e740b6"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Use With Other, Lamivudine-, Zidovudine-, and/or Emtricitabine-Containing Products</h2>
<p class="First">COMBIVIR is a fixed-dose combination of lamivudine and zidovudine. COMBIVIR should not be administered concomitantly with other lamivudine- or zidovudine-containing products including EPIVIR<span class="Sup">Â®</span> (lamivudine) Tablets and Oral Solution, EPIVIR-HBV Tablets and Oral Solution, RETROVIR<span class="Sup">Â®</span> (zidovudine) Tablets, Capsules, Syrup, and IV Infusion, EPZICOM<span class="Sup">Â®</span> (abacavir sulfate and lamivudine) Tablets, or TRIZIVIR<span class="Sup">Â®</span> (abacavir sulfate, lamivudine, and zidovudine) Tablets; or emtricitabine-containing products, including ATRIPLA<span class="Sup">Â®</span> (efavirenz, emtricitabine, and tenofovir), EMTRIVA<span class="Sup">Â®</span> (emtricitabine), or TRUVADA<span class="Sup">Â®</span> (emtricitabine and tenofovir) or COMPLERA<span class="Sup">â„¢</span> (rilpivirine/emtricitabine/tenofovir).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ccf922c2-3085-428d-a564-cd23e5aad1c3"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Use With Interferon- and Ribavirin-Based Regimens</h2>
<p class="First">InÂ vitro studies have shown ribavirin can reduce the phosphorylation of pyrimidine nucleoside analogues such as lamivudine and zidovudine. Although no evidence of a pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with lamivudine or zidovudine in HIV-1/HCV co-infected patients <span class="Italics">[see Clinical Pharmacology (12.3)]</span>, hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin. Patients receiving interferon alfa with or without ribavirin and COMBIVIR should be closely monitored for treatment-associated toxicities, especially hepatic decompensation, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Discontinuation of COMBIVIR should be considered as medically appropriate. Dose reduction or discontinuation of interferon alfa, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Child-Pugh greater than 6) (see the complete prescribing information for interferon and ribavirin).</p>
<p>Exacerbation of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Coadministration of ribavirin and zidovudine is not advised.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8bde122d-3b24-44c9-90e9-2b408c345116"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First">COMBIVIR should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> or other significant risk factors for the development of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Treatment with COMBIVIR should be stopped immediately if clinical signs, symptoms, or laboratory abnormalities suggestive of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occur <span class="Italics">[see Adverse Reactions (6.1)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_719181fd-0fc9-42ea-a55f-7ba86fdee91a"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including COMBIVIR. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Gravesâ€™ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-BarrÃ© syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d395abf0-0ae9-4bc0-be7e-67e5b8b5387a"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and â€œcushingoid appearanceâ€? have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_697a1a50-6b29-4b99-8eb2-aaf1d14c2c09"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul>
<li>Hematologic toxicity, including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)].</span>
</li>
<li>Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.2)].</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.3)].</span>
</li>
<li>Acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.4)].</span>
</li>
<li>Hepatic decompensation in patients co-infected with HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="Italics">[see Warnings and Precautions (5.6)].</span>
</li>
<li>Exacerbation of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine <span class="Italics">[see Warnings and Precautions (5.6)].</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> <span class="Italics">[see Warnings and Precautions (5.7)].</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a2acd8ab-c828-4c6d-819f-63785ea8c83c"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Underline">Lamivudine Plus Zidovudine Administered As Separate Formulations:</span> In 4Â randomized, controlled trials of EPIVIR 300Â mg per day plus RETROVIR 600Â mg per day, the following selected adverse reactions and laboratory abnormalities were observed (see Tables 1 and 2).</p>
<a name="id_8812c922-7046-4bbc-a800-98fdb8d60b56"></a><table border="single" width="539.000">
<caption><span>Table 1. Selected Clinical Adverse Reactions (â‰¥5% Frequency) in 4 Controlled Clinical Trials With EPIVIR 300Â mg/day and RETROVIR 600Â mg/day</span></caption>
<col width="60.9%">
<col width="39.1%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">Adverse Reaction</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">EPIVIR plus RETROVIR</p>(nÂ =Â 251)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Body as a whole</span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center" valign="top">35%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span> &amp; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></td>
<td class="Rrule" align="center" valign="top">27%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></td>
<td class="Rrule" align="center" valign="top">10%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Digestive</span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center" valign="top">33%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center" valign="top">18%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> &amp; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td class="Rrule" align="center" valign="top">13%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></td>
<td class="Rrule" align="center" valign="top">10%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center" valign="top">9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal cramps</span></td>
<td class="Rrule" align="center" valign="top">6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center" valign="top">5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Nervous system</span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td class="Rrule" align="center" valign="top">12%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> &amp; other <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span></td>
<td class="Rrule" align="center" valign="top">11%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center" valign="top">10%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive disorders</span></td>
<td class="Rrule" align="center" valign="top">9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Respiratory</span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Nasal signs &amp; symptoms</td>
<td class="Rrule" align="center" valign="top">20%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center" valign="top">18%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Skin</span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span></td>
<td class="Rrule" align="center" valign="top">9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Musculoskeletal</span></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td class="Rrule" align="center" valign="top">12%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center" valign="top">8%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Botrule Rrule" align="center" valign="top">5%</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> was observed in 9 of the 2,613Â adult patients (0.3%) who received EPIVIR in controlled clinical trials<span class="Italics"> [see Warnings and Precautions (5.7)]</span>.</p>
<p>Selected laboratory abnormalities observed during therapy are listed in TableÂ 2.</p>
<a name="id_6f8c72f9-50bb-46e6-85f0-fc5011fffe13"></a><table border="single" width="471.000">
<caption><span>Table 2. Frequencies of Selected Laboratory Abnormalities Among Adults in 4 Controlled Clinical Trials of EPIVIR 300Â mg/day plus RETROVIR 600Â mg/day<span class="Sup">a</span></span></caption>
<col width="48.6%">
<col width="51.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">Test</p>(Abnormal Level)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">EPIVIR plus RETROVIR</p>%Â (n)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (ANC&lt;750/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center" valign="top">7.2% (237)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb&lt;8.0Â g/dL)</td>
<td class="Rrule" align="center" valign="top">2.9% (241)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> (platelets&lt;50,000/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center" valign="top">0.4% (240)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">ALT (&gt;5.0 x ULN)</td>
<td class="Rrule" align="center" valign="top">3.7% (241)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">AST (&gt;5.0 x ULN)</td>
<td class="Rrule" align="center" valign="top">1.7% (241)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Bilirubin (&gt;2.5 x ULN)</td>
<td class="Rrule" align="center" valign="top">0.8% (241)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Amylase (&gt;2.0 x ULN)</td>
<td class="Botrule Rrule" align="center" valign="top">4.2% (72)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="2" valign="top">ULNÂ =Â Upper limit of normal.</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2" valign="top">ANCÂ =Â Absolute neutrophil count.</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="2" valign="top">nÂ =Â Number of patients assessed.</td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top">
<span class="Sup">a</span> Frequencies of these laboratory abnormalities were higher in patients with mild laboratory abnormalities at baseline.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf39b8b7-cdca-4c1e-9462-7e6a92177c87"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">In addition to adverse reactions reported from clinical trials, the following reactions have been identified during post-approval use of EPIVIR, RETROVIR, and/or COMBIVIR. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to EPIVIR, RETROVIR, and/or COMBIVIR.</p>
<p><span class="Underline">Body as a Whole:</span> Redistribution/accumulation of body fat <span class="Italics">[see Warnings and Precautions (5.9)]</span>.</p>
<p><span class="Underline">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>.</p>
<p><span class="Underline">Endocrine and Metabolic:</span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p><span class="Underline">Gastrointestinal:</span> Oral mucosal <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>.</p>
<p><span class="Underline">General:</span> <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
<p><span class="Underline">Hemic and Lymphatic:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, (including pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span> progressing on therapy), <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>.</p>
<p><span class="Underline">Hepatic and Pancreatic:</span> <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, posttreatment exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.3), (5.4), (5.7)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> Sensitization reactions (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Underline">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span>, CPK elevation, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="Underline">Nervous:</span> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p><span class="Underline">Respiratory:</span> Abnormal breath sounds/<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>.</p>
<p><span class="Underline">Skin:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_26e1e87d-669b-487c-a498-9690f34d90e6"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No drug interaction studies have been conducted using COMBIVIR Tablets <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8f7b5cc-612b-40fd-88ad-2ec1e11ba8dd"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Antiretroviral Agents</h2>
<p class="First"><span class="Underline">Lamivudine:</span><span class="Italics">Zalcitabine: </span>Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another. Therefore, use of COMBIVIR in combination with zalcitabine is not recommended.</p>
<p><span class="Underline">Zidovudine:</span><span class="Italics">Stavudine: </span>Concomitant use of COMBIVIR with stavudine should be avoided since an antagonistic relationship with zidovudine has been demonstrated inÂ vitro.</p>
<p><span class="Italics">Nucleoside Analogues Affecting DNA Replication: </span>Some nucleoside analogues affecting DNA replication, such as ribavirin, antagonize the inÂ vitro antiviral activity of zidovudine against HIV-1; concomitant use of such drugs should be avoided.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a9fcd53-925d-470f-a8ab-8d94376dce9f"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Doxorubicin</h2>
<p class="First"><span class="Underline">Zidovudine:</span> Concomitant use of COMBIVIR with doxorubicin should be avoided since an antagonistic relationship with zidovudine has been demonstrated inÂ vitro.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cbb69c6c-ba14-48a1-bb0e-48eb71fc2123"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Hematologic/Bone Marrow Suppressive/Cytotoxic Agents</h2>
<p class="First"><span class="Underline">Zidovudine:</span> Coadministration of ganciclovir, interferon alfa, ribavirin, and other bone marrow suppressive or cytotoxic agents may increase the hematologic toxicity of zidovudine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c980c7a7-8795-46b7-ac56-ac251dc445da"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Interferon- and Ribavirin-Based Regimens</h2>
<p class="First"><span class="Underline">Lamivudine:</span> Although no evidence of a pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with lamivudine in HIV-1/HCV co-infected patients, hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin<span class="Italics"> [see Warnings and Precautions (5.5), Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f6403ff-a1d0-48cd-b02e-857c8fd24137"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Trimethoprim/Sulfamethoxazole (TMP/SMX)</h2>
<p class="First"><span class="Underline">Lamivudine:</span> No change in dose of either drug is recommended. There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat PCP.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_24eb4ab2-0bf0-42c7-823d-971176ceea39"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_5c5703f6-6060-4ce9-aac8-32d3fa0de1f2"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C.</p>
<p><span class="Underline">Fetal Risk Summary:</span> There are no adequate and well-controlled studies of COMBIVIR (lamivudine and zidovudine) in pregnant women. Clinical trial data demonstrate that maternal zidovudine treatment during pregnancy reduces vertical transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to the fetus. Animal reproduction studies performed with lamivudine and zidovudine showed increased embryotoxicity and <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (zidovudine), and increased embryolethality (lamivudine). COMBIVIR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Italics">Antiretroviral Pregnancy Registry:</span> To monitor maternal-fetal outcomes of pregnant women exposed to COMBIVIR and other antiretroviral agents, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
<p><span class="Underline">Clinical Considerations:</span> Treatment of HIV during pregnancy optimizes the health of both mother and fetus. Clinical trial data reviewed by FDA demonstrate that maternal zidovudine treatment significantly reduces vertical transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to the fetus <span class="Italics">[see Clinical Studies (14.2)]</span>. Published data suggest that combination antiretroviral regimens may reduce the rate of vertical transmission even further.</p>
<p>Pharmacokinetics of lamivudine and zidovudine in pregnant women are similar to the pharmacokinetics in nonpregnant women. No dose adjustments are needed during pregnancy.</p>
<p>In a clinical trial, adverse events among HIV-1-infected women were not different among untreated women and women treated with zidovudine. It is not known whether risks of adverse events associated with lamivudine are altered in pregnant women compared with other HIV-1-infected patients (see Human data below).</p>
<p><span class="Underline">Data:</span><span class="Italics">Human Data: </span><span class="Italics">Lamivudine: </span>Lamivudine pharmacokinetics were studied in pregnant women during 2Â clinical studies conducted in South Africa. The study assessed pharmacokinetics in: 16Â women at 36Â weeks gestation using 150Â mg lamivudine twice daily with zidovudine, 10Â women at 38Â weeks gestation using 150Â mg lamivudine twice daily with zidovudine, and 10Â women at 38Â weeks gestation using lamivudine 300Â mg twice daily without other antiretrovirals. Lamivudine pharmacokinetics in pregnant women were similar to those seen in nonpregnant adults and in postpartum women. Lamivudine concentrations were generally similar in maternal, neonatal, and umbilical cord serum samples.</p>
<p><span class="Italics">Zidovudine: </span>A randomized, double-blind, placebo-controlled trial was conducted in HIV-1-infected pregnant women to determine the utility of zidovudine for the prevention of maternal-fetal HIV-1 transmission. Zidovudine treatment during pregnancy reduced the rate of maternal-fetal HIV-1 transmission from 24.9% for infants born to placebo-treated mothers to 7.8% for infants born to mothers treated with zidovudine. There were no differences in pregnancy-related adverse events between the treatment groups. Congenital abnormalities occurred with similar frequency between neonates born to mothers who received zidovudine and neonates born to mothers who received placebo. The observed abnormalities included problems in embryogenesis (prior to 14 weeks) or were recognized on ultrasound before or immediately after initiation of study drug <span class="Italics">[see Clinical Studies (14.2)]</span>.</p>
<p>Zidovudine pharmacokinetics were studied in a PhaseÂ 1 study of 8Â women during the last trimester of pregnancy. As pregnancy progressed, there was no evidence of drug accumulation. The pharmacokinetics of zidovudine were similar to that of nonpregnant adults. Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery.</p>
<p><span class="Italics">Animal Data: </span><span class="Italics">Lamivudine: </span>Animal reproduction studies performed at oral doses up to 130 and 60Â times the adult dose in rats and rabbits, respectively, revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> due to lamivudine. Increased early embryolethality occurred in rabbits at exposure levels similar to those in humans. However, there was no indication of this effect in rats at exposure levels up to 35Â times those in humans. Based on animal studies, lamivudine crosses the placenta and is transferred to the fetus <span class="Italics">[see Nonclinical Toxicology (13.2)].</span></p>
<p><span class="Italics">Zidovudine: </span>Increased fetal resorptions occurred in pregnant rats and rabbits treated with doses of zidovudine that produced drug plasma concentrations 66 to 226Â times (rats) and 12Â to 87Â times (rabbits) the mean steady-state peak human plasma concentration following a single 100-mg dose of zidovudine. There were no other reported developmental anomalies. In another developmental toxicity study, pregnant rats received zidovudine up to near-lethal doses that produced peak plasma concentrations 350 times peak human plasma concentrations (300Â times the daily exposure [AUC] in humans given 600Â mg/day zidovudine). This dose was associated with marked maternal toxicity and an increased incidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. However, there were no signs of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at doses up to one-fifth the lethal dose <span class="Italics">[see Nonclinical Toxicology</span><span class="Italics">(13.2)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d9e6f009-0d43-4ff1-bf19-d5479bff3f9b"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Because of both the potential for HIV-1 transmission and serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed if they are receiving COMBIVIR.</p>
<p>Although no studies of COMBIVIR excretion in breast milk have been performed, lactation studies performed with lamivudine and zidovudine show that both drugs are excreted in human breast milk. Samples of breast milk obtained from 20Â mothers receiving lamivudine monotherapy (300Â mg twice daily) or combination therapy (150Â mg lamivudine twice daily and 300Â mg zidovudine twice daily) had measurable concentrations of lamivudine. In another study, after administration of a single dose of 200Â mg zidovudine to 13Â HIV-1-infected women, the mean concentration of zidovudine was similar in human milk and serum.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_dc61e3a2-7444-4b6a-871c-c2158ae60d2c"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">COMBIVIR should not be administered to pediatric patients weighing less than 30Â kg, because it is a fixed-dose combination that cannot be adjusted for this patient population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_7310f210-a1f7-43a7-9998-7c28dd836ce9"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of COMBIVIR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. COMBIVIR is not recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (i.e., creatinine clearance less than 50Â mL/min) because it is a fixed-dose combination that cannot be adjusted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1d5c9735-c734-4779-a232-fbeb4288c0b8"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Reduction of the dosages of lamivudine and zidovudine is recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Patients with creatinine clearance less than 50Â mL/min should not receive COMBIVIR because it is a fixed-dose combination that cannot be adjusted<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c53e427-a712-4b8b-ba94-0c98bf7c8ee3"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">A reduction in the daily dose of zidovudine may be necessary in patients with mild to moderate impaired hepatic function or <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">liver cirrhosis</span>. COMBIVIR is not recommended for patients with impaired hepatic function because it is a fixed-dose combination that cannot be adjusted.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_53ca6037-3206-44bd-a63f-7dd5ce38b2bd"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="Bold">COMBIVIR:</span> There is no known antidote for COMBIVIR.</p>
<p><span class="Bold">Lamivudine:</span> One case of an adult ingesting 6Â grams of lamivudine was reported; there were no clinical signs or symptoms noted and hematologic tests remained normal. Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> event.</p>
<p><span class="Bold">Zidovudine:</span> <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute overdoses</span> of zidovudine have been reported in pediatric patients and adults. These involved exposures up to 50Â grams. The only consistent findings were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Other reported occurrences included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and 1Â report of a <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal seizure</span>. Hematologic changes were transient. All patients recovered. Hemodialysis and peritoneal dialysis appear to have a negligible effect on the removal of zidovudine, while elimination of its primary metabolite, 3â€²-azido-3â€²-deoxy-5â€²-<span class="Italics">O</span>-Î²-<span class="Italics">D</span>-glucopyranuronosylthymidine (GZDV), is enhanced.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c8639649-b38a-4381-bdef-5172799d83b5"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"><span class="Underline">COMBIVIR:</span> COMBIVIR Tablets are combination tablets containing lamivudine and zidovudine. Lamivudine (EPIVIR) and zidovudine (RETROVIR, azidothymidine, AZT, or ZDV) are synthetic nucleoside analogues with activity against HIV-1.</p>
<p>COMBIVIR Tablets are for oral administration. Each film-coated tablet contains 150Â mg of lamivudine, 300Â mg of zidovudine, and the inactive ingredients colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate, and titanium dioxide.</p>
<p><span class="Underline">Lamivudine:</span> The chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2â€²,3â€²-dideoxy, 3â€²-thiacytidine. It has a molecular formula of C<span class="Sub">8</span>H<span class="Sub">11</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S and a molecular weight of 229.3. It has the following structural formula:</p>
<div class="Figure"><img alt="lamivudine chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=479a2784-8db2-4fe5-94ba-55316a3c4e4f&amp;name=8fada68f-f4a9-4359-ba7d-d66c835da3a5-01.jpg"></div>
<p>Lamivudine is a white to off-white crystalline solid with a solubility of approximately 70Â mg/mL in water at 20Â°C.</p>
<p><span class="Underline">Zidovudine:</span> The chemical name of zidovudine is 3â€²-azido-3â€²-deoxythymidine. It has a molecular formula of C<span class="Sub">10</span>H<span class="Sub">13</span>N<span class="Sub">5</span>O<span class="Sub">4</span> and a molecular weight of 267.24. It has the following structural formula:</p>
<div class="Figure"><img alt="zidovudine chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=479a2784-8db2-4fe5-94ba-55316a3c4e4f&amp;name=8fada68f-f4a9-4359-ba7d-d66c835da3a5-02.jpg"></div>
<p>Zidovudine is a white to beige, odorless, crystalline solid with a solubility of 20.1Â mg/mL in water at 25Â°C.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_a4219bc6-018e-46ab-9298-4a267622e60c"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_c16223f1-5a01-4241-9875-61c419ec09b3"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">COMBIVIR is an antiviral agent <span class="Italics">[see Clinical Pharmacology (12.4)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_0160d0e9-ffb7-4645-978b-1883e103b97a"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Pharmacokinetics in Adults:</span><span class="Italics">COMBIVIR:</span> One COMBIVIR Tablet was bioequivalent to 1 EPIVIR Tablet (150Â mg) plus 1 RETROVIR Tablet (300Â mg) following single-dose administration to fasting healthy subjects (nÂ =Â 24).</p>
<p><span class="Italics">Lamivudine:</span> The pharmacokinetic properties of lamivudine in fasting patients are summarized in TableÂ 3. Following oral administration, lamivudine is rapidly absorbed and extensively distributed. Binding to plasma protein is low. Approximately 70% of an intravenous dose of lamivudine is recovered as unchanged drug in the urine. Metabolism of lamivudine is a minor route of elimination. In humans, the only known metabolite is the trans-sulfoxide metabolite (approximately 5% of an oral dose after 12Â hours).</p>
<p><span class="Italics">Zidovudine:</span> The pharmacokinetic properties of zidovudine in fasting patients are summarized in TableÂ 3. Following oral administration, zidovudine is rapidly absorbed and extensively distributed. Binding to plasma protein is low. Zidovudine is eliminated primarily by hepatic metabolism. The major metabolite of zidovudine is GZDV. GZDV area under the curve (AUC) is about 3-fold greater than the zidovudine AUC. Urinary recovery of zidovudine and GZDV accounts for 14% and 74% of the dose following oral administration, respectively. A second metabolite, 3â€²-amino-3â€²-deoxythymidine (AMT), has been identified in plasma. The AMT AUC was one fifth of the zidovudine AUC.</p>
<a name="id_a88fe918-f924-4490-bb02-7110fef9c812"></a><table width="719.000">
<caption><span>Table 3. Pharmacokinetic Parameters<span class="Sup">a</span> for Lamivudine and Zidovudine in Adults</span></caption>
<col width="36.9%">
<col width="20.0%">
<col width="9.3%">
<col width="22.5%">
<col width="11.3%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Parameter</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Lamivudine</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Zidovudine</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Oral bioavailability (%)</td>
<td align="center" valign="top">86 Â± 16</td>
<td class="Rrule" align="center" valign="top">NÂ =Â 12</td>
<td align="center" valign="top">64 Â± 10</td>
<td class="Rrule" align="center" valign="top">nÂ =Â 5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Apparent volume of distribution (L/kg)</td>
<td align="center" valign="top">1.3 Â± 0.4</td>
<td class="Rrule" align="center" valign="top">NÂ =Â 20</td>
<td align="center" valign="top">1.6 Â± 0.6</td>
<td class="Rrule" align="center" valign="top">nÂ =Â 8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Plasma protein binding (%)</td>
<td align="center" valign="top">&lt;36</td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top">&lt;38</td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">CSF:plasma ratio<span class="Sup">b</span>
</td>
<td align="center" valign="top">0.12 [0.04 to 0.47]</td>
<td class="Rrule" align="center" valign="top">nÂ =Â 38<span class="Sup">c</span>
</td>
<td align="center" valign="top">0.60 [0.04 to 2.62]</td>
<td class="Rrule" align="center" valign="top">NÂ =Â 39<span class="Sup">d</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Systemic clearance (L/hr/kg)</td>
<td align="center" valign="top">0.33 Â± 0.06</td>
<td class="Rrule" align="center" valign="top">NÂ =Â 20</td>
<td align="center" valign="top">1.6 Â± 0.6</td>
<td class="Rrule" align="center" valign="top">nÂ =Â 6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Renal clearance (L/hr/kg)</td>
<td align="center" valign="top">0.22Â Â±Â 0.06</td>
<td class="Rrule" align="center" valign="top">NÂ =Â 20</td>
<td align="center" valign="top">0.34 Â± 0.05</td>
<td class="Rrule" align="center" valign="top">nÂ =Â 9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Elimination half-life (hr)<span class="Sup">e</span>
</td>
<td class="Botrule" align="center" valign="top">5 to 7</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">0.5 to 3</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top">
<span class="Sup">a</span> Data presented as mean Â± standard deviation except where noted.</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top">
<span class="Sup">b</span> Median [range].</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top">
<span class="Sup">c</span> Children.</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top">
<span class="Sup">d</span> Adults.</td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top">
<span class="Sup">e</span> Approximate range.</td></tr>
</tbody>
</table>
<p><span class="Italics">Effect of Food on Absorption of COMBIVIR: </span>COMBIVIR may be administered with or without food. The lamivudine and zidovudine AUC following administration of COMBIVIR with food was similar when compared to fasting healthy subjects (nÂ =Â 24).</p>
<p><span class="Underline">Special Populations:</span></p>
<p><span class="Italics">Pregnancy: </span><span class="Italics">See Use in Specific Populations (8.1)</span>.</p>
<p><span class="Italics">COMBIVIR: </span>No data are available.</p>
<p><span class="Italics">Zidovudine: </span>Zidovudine pharmacokinetics has been studied in a PhaseÂ 1 study of 8Â women during the last trimester of pregnancy. As pregnancy progressed, there was no evidence of drug accumulation. The pharmacokinetics of zidovudine was similar to that of nonpregnant adults. Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery. Although data are limited, methadone maintenance therapy in 5Â pregnant women did not appear to alter zidovudine pharmacokinetics. In a nonpregnant adult population, a potential for interaction has been identified.</p>
<p><span class="Italics">Nursing Mothers: </span><span class="Italics">See Use in Specific Populations (8.3)</span>.</p>
<p><span class="Underline">Pediatric Patients:</span> COMBIVIR should not be administered to pediatric patients weighing less than 30Â kg.</p>
<p><span class="Underline">Geriatric Patients:</span> The pharmacokinetics of lamivudine and zidovudine have not been studied in patients over 65Â years of age.</p>
<p><span class="Underline">Gender:</span> A pharmacokinetic study in healthy male (nÂ =Â 12) and female (nÂ =Â 12) subjects showed no gender differences in zidovudine AUC<span class="Sub">âˆž</span> or lamivudine AUC<span class="Sub">âˆž</span> normalized for body weight.</p>
<p><span class="Underline">Race:</span><span class="Italics"> Lamivudine: </span>There are no significant racial differences in lamivudine pharmacokinetics.</p>
<p><span class="Italics">Zidovudine: </span>The pharmacokinetics of zidovudine with respect to race have not been determined.</p>
<p><span class="Underline">Drug Interactions:</span><span class="Italics"> See Drug Interactions (7).</span></p>
<p>No drug interaction studies have been conducted using COMBIVIR Tablets. However, Table 4 presents drug interaction information for the individual components of COMBIVIR.</p>
<p><span class="Italics">Lamivudine Plus Zidovudine: </span>No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed in 12Â asymptomatic HIV-1-infected adult patients given a single dose of zidovudine (200Â mg) in combination with multiple doses of lamivudine (300Â mg q 12Â hr).</p>
<a name="id_17ac3a83-5173-484f-b257-16b62eabadfc"></a><table width="589.000">
<caption><span>Table 4. Effect of Coadministered Drugs on Lamivudine and Zidovudine AUC<span class="Sup">a</span></span></caption>
<col width="27.5%">
<col width="19.9%">
<col width="7.6%">
<col width="14.4%">
<col width="16.8%">
<col width="13.8%">
<tbody class="Headless">
<tr class="First"><td class="Botrule" align="left" colspan="6" valign="top"><span class="Bold">Note: ROUTINE DOSE MODIFICATION OF LAMIVUDINE AND ZIDOVUDINE IS NOT WARRANTED WITH COADMINISTRATION OF THE FOLLOWING DRUGS.</span></td></tr>
<tr><td class="Botrule" align="center" colspan="6" valign="top"><span class="Bold">Drugs That May Alter Lamivudine Blood Concentrations</span></td></tr>
<tr>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom"><span class="Bold">Coadministered Drug and Dose</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom"><span class="Bold">Lamivudine Dose</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom"><span class="Bold">n</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">Lamivudine </span></p>
<span class="Bold">Concentrations</span>
</td>
<td class="Botrule" align="center" rowspan="2" valign="bottom"><span class="Bold">Concentration of Coadministered Drug</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">AUC</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Variability</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Nelfinavir</p>Â Â Â 750Â mg qÂ 8Â hr x 7 to 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">single 150Â mg</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘AUC 10%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">95% CI:</p>1% to 20%</td>
<td class="Botrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Trimethoprim 160Â mg/Sulfamethoxazole</p>Â Â Â 800Â mg daily x 5Â days</td>
<td class="Botrule Rrule" align="center" valign="top">single 300Â mg</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘AUC 43%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">90% CI:</p>32% to 55%</td>
<td class="Botrule" align="center" valign="top">â†”</td>
</tr>
<tr><td class="Botrule" align="center" colspan="6" valign="top"><span class="Bold">Drugs That May Alter Zidovudine Blood Concentrations</span></td></tr>
<tr>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom"><span class="Bold">Coadministered Drug and Dose</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom"><span class="Bold">Zidovudine Dose</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom"><span class="Bold">n</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">
<p class="First"><span class="Bold">Zidovudine </span></p>
<span class="Bold">Concentrations</span>
</td>
<td class="Botrule" align="center" rowspan="2" valign="bottom"><span class="Bold">Concentration of Coadministered Drug</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">AUC</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Variability</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Atovaquone</p>Â Â Â 750Â mg q 12Â hr with food</td>
<td class="Botrule Rrule" align="center" valign="top">200Â mg q 8Â hr</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘AUC 31%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>23% to 78%<span class="Sup">b</span>
</td>
<td class="Botrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Clarithromycin</p>Â Â Â 500 mg twice daily</td>
<td class="Botrule Rrule" align="center" valign="top">100 mg q 4 hr x 7 days</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">â†“AUC 12%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>
<p>â†“34% to â†‘14%</p>
</td>
<td class="Botrule" align="center" valign="top">Not Reported</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Fluconazole</p>Â Â Â 400Â mg daily</td>
<td class="Botrule Rrule" align="center" valign="top">200Â mg q 8Â hr</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘AUC 74%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">95% CI:</p>54% to 98%</td>
<td class="Botrule" align="center" valign="top">Not Reported</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Methadone</p>Â Â Â 30 to 90Â mg daily</td>
<td class="Botrule Rrule" align="center" valign="top">200Â mg q 4Â hr</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘AUC 43%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>16% to 64%<span class="Sup">b</span>
</td>
<td class="Botrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Nelfinavir</p>Â Â Â 750Â mgÂ q 8Â hr x 7 to 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">single 200Â mg</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">â†“AUC 35%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>28% to 41%</td>
<td class="Botrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Probenecid </p>Â Â Â 500 mg q 6Â hr x 2Â days</td>
<td class="Botrule Rrule" align="center" valign="top">2Â mg/kg q 8Â hr x 3Â days</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘AUC 106%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>100% to 170%<span class="Sup">b</span>
</td>
<td class="Botrule" align="center" valign="top">Not Assessed</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Rifampin</p>Â Â Â 600Â mg daily x 14 days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">200Â mg q 8Â hr</p>X 14Â days</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“AUC</p>47%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">90% CI:</p>41% to 53%</td>
<td class="Botrule" align="center" valign="top">Not Assessed</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Ritonavir</p>Â Â Â 300Â mg q 6Â hr x 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">200 mg q 8Â hr x 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">â†“AUC 25%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">95% CI:</p>15% to 34%</td>
<td class="Botrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Valproic acid </p>Â Â Â 250Â mg or 500Â mg q 8Â hr x 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">100 mg q 8Â hr x 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘AUC 80%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Range</p>64% to 130%<span class="Sup">b</span>
</td>
<td class="Botrule" align="center" valign="top">Not Assessed</td>
</tr>
<tr><td align="left" colspan="6" valign="top">â†‘ = Increase; â†“= Decrease; â†”Â =Â no significant change; AUC = area under the concentration versus time curve; CI = confidence interval.</td></tr>
<tr><td align="left" colspan="6" valign="top">
<span class="Sup">a</span> This table is not all inclusive.</td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="6" valign="top">
<span class="Sup">b</span> Estimated range of percent difference.</td></tr>
</tbody>
</table>
<p><span class="Italics">Ribavirin: </span>InÂ vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (nÂ =Â 18), stavudine (nÂ =Â 10), or zidovudine (nÂ =Â 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients <span class="Italics">[see Warnings and Precautions (5.5)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d7362b8b-72cb-4084-a1e4-461cd5fd59ce"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Underline">Mechanism of Action:</span><span class="Italics"> Lamivudine:</span> Intracellularly, lamivudine is phosphorylated to its active 5â€²-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. 3TC-TP is a weak inhibitor of cellular DNA polymerases Î±, Î², and Î³.</p>
<p><span class="Italics">Zidovudine: </span>Intracellularly, zidovudine is phosphorylated to its active 5â€²-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). The principal mode of action of ZDV-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue. ZDV-TP is a weak inhibitor of the cellular DNA polymerases Î± and Î³ and has been reported to be incorporated into the DNA of cells in culture.</p>
<p><span class="Underline">Antiviral Activity:</span><span class="Italics"> Lamivudine Plus Zidovudine: </span>In HIV-1â€“infected MT-4 cells, lamivudine in combination with zidovudine at various ratios exhibited synergistic antiretroviral activity.</p>
<p><span class="Italics">Lamivudine: </span>The antiviral activity of lamivudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) using standard susceptibility assays. EC<span class="Sub">50</span> values (50% effective concentrations) were in the range of 0.003 to 15Â Î¼M (1Â Î¼MÂ =Â 0.23Â mcg/mL). HIV-1 from therapy-naive subjects with no amino acid substitutions associated with resistance gave median EC<span class="Sub">50</span> values of 0.429Â ÂµM (range: 0.200 to 2.007Â ÂµM) from Virco (nÂ =Â 92 baseline samples from COL40263) and 2.35Â ÂµM (1.37 to 3.68Â ÂµM) from Monogram Biosciences (nÂ =Â 135 baseline samples from ESS30009). The EC<span class="Sub">50</span> values of lamivudine against different HIV-1 clades (A-G) ranged from 0.001 to 0.120Â ÂµM, and against HIV-2 isolates from 0.003 to 0.120Â Î¼M in peripheral blood mononuclear cells. Ribavirin (50Â Î¼M) decreased the anti-HIV-1 activity of lamivudine by 3.5Â fold in MT-4 cells.</p>
<p><span class="Italics">Zidovudine: </span>The antiviral activity of zidovudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>). The EC<span class="Sub">50</span> and EC<span class="Sub">90</span> values for zidovudine were 0.01 to 0.49Â ÂµM (1Â Î¼MÂ =Â 0.27Â mcg/mL) and 0.1 to 9Â Î¼M, respectively. HIV-1 from therapy-naive subjects with no amino acid substitutions associated with resistance gave median EC<span class="Sub">50</span> values of 0.011Â ÂµM (range: 0.005 to 0.110Â ÂµM) from Virco (nÂ =Â 92 baseline samples from COL40263) and 0.0017Â ÂµM (0.006 to 0.0340Â ÂµM) from Monogram Biosciences (nÂ =Â 135 baseline samples from ESS30009). The EC<span class="Sub">50</span> values of zidovudine against different HIV-1 clades (A-G) ranged from 0.00018 to 0.02Â Î¼M, and against HIV-2 isolates from 0.00049 to 0.004Â Î¼M. In cell culture drug combination studies, zidovudine demonstrates synergistic activity with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir, didanosine, lamivudine, and zalcitabine; the non-nucleoside reverse transcriptase inhibitors (NNRTIs) delavirdine and nevirapine; and the protease inhibitors (PIs) indinavir, nelfinavir, ritonavir, and saquinavir; and additive activity with interferon alfa. Ribavirin has been found to inhibit the phosphorylation of zidovudine in cell culture.</p>
<p><span class="Underline">Resistance:</span><span class="Italics"> Lamivudine Plus Zidovudine Administered As Separate Formulations: </span>In patients receiving lamivudine monotherapy or combination therapy with lamivudine plus zidovudine, HIV-1 isolates from most patients became phenotypically and genotypically resistant to lamivudine within 12Â weeks. In some patients harboring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12Â weeks of treatment with lamivudine and zidovudine. Combination therapy with lamivudine plus zidovudine delayed the emergence of amino acid substitutions conferring resistance to zidovudine.</p>
<p>HIV-1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> resistant to both lamivudine and zidovudine have been isolated from patients after prolonged lamivudine/zidovudine therapy. Dual resistance required the presence of multiple amino acid substitutions, the most essential of which may be G333E. The incidence of dual resistance and the duration of combination therapy required before dual resistance occurs are unknown.</p>
<p><span class="Italics">Lamivudine: </span>Lamivudine-resistant isolates of HIV-1 have been selected in cell culture and have also been recovered from patients treated with lamivudine or lamivudine plus zidovudine. Genotypic analysis of isolates selected in cell culture and recovered from lamivudine-treated patients showed that the resistance was due to a specific amino acid substitution in the HIV-1 reverse transcriptase at codonÂ 184 changing the methionine to either isoleucine or valine (M184V/I).</p>
<p><span class="Italics">Zidovudine: </span>HIV-1 isolates with reduced susceptibility to zidovudine have been selected in cell culture and were also recovered from patients treated with zidovudine. Genotypic analyses of the isolates selected in cell culture and recovered from zidovudine-treated patients showed substitutions in the HIV-1 RT gene resulting in 6Â amino acid substitutions (M41L, D67N, K70R, L210W, T215Y or F, and K219Q) that confer zidovudine resistance. In general, higher levels of resistance were associated with greater number of amino acid substitutions.</p>
<p><span class="Underline">Cross-Resistance:</span> Cross-resistance has been observed among NRTIs.</p>
<p><span class="Italics">Lamivudine Plus Zidovudine: </span>Cross-resistance between lamivudine and zidovudine has not been reported. In some patients treated with lamivudine alone or in combination with zidovudine, isolates have emerged with a substitution at codonÂ 184, which confers resistance to lamivudine. Cross-resistance to abacavir, didanosine, tenofovir, and zalcitabine has been observed in some patients harboring lamivudine-resistant HIV-1 isolates. In some patients treated with zidovudine plus didanosine or zalcitabine, isolates resistant to multiple drugs, including lamivudine, have emerged (see under Zidovudine below).</p>
<p><span class="Italics">Lamivudine: </span>See Lamivudine Plus Zidovudine (above).</p>
<p><span class="Italics">Zidovudine: </span>In a study of 167Â HIV-1-infected patients, isolates (nÂ =Â 2) with multi-<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine were recovered from patients treated for â‰¥1Â year with zidovudine plus didanosine or zidovudine plus zalcitabine. The pattern of resistance-associated amino acid substitutions with such combination therapies was different (A62V, V75I, F77L, F116Y, Q151M) from the pattern with zidovudine monotherapy, with the Q151MÂ substitution being most commonly associated with multi-<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>. The substitution at codonÂ 151 in combination with substitutions at 62, 75, 77, and 116 results in a virus with reduced susceptibility to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine. Thymidine analogue mutations (TAMs) are selected by zidovudine and confer cross-resistance to abacavir, didanosine, stavudine, tenofovir, and zalcitabine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_68921e12-8509-440c-bc73-beccb0c9e64d"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_cd4676de-6847-4127-b0fa-5dd6449a9655"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenicity:</span><span class="Italics"> Lamivudine: </span>Long-term carcinogenicity studies with lamivudine in mice and rats showed no evidence of carcinogenic potential at exposures up to 10Â times (mice) and 58Â times (rats) those observed in humans at the recommended therapeutic dose for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Italics">Zidovudine: </span>Zidovudine was administered orally at 3Â dosage levels to separate groups of mice and rats (60Â females and 60Â males in each group). Initial single daily doses were 30, 60, and 120Â mg/kg/day in mice and 80, 220, and 600Â mg/kg/day in rats. The doses in mice were reduced to 20, 30, and 40Â mg/kg/day after dayÂ 90 because of treatment-related <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, whereas in rats only the high dose was reduced to 450Â mg/kg/day on dayÂ 91 and then to 300Â mg/kg/day on dayÂ 279.</p>
<p>In mice, 7Â late-appearing (after 19Â months) vaginal neoplasms (5Â nonmetastasizing squamous cell carcinomas, 1Â squamous cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span>, and 1Â squamous <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyp</span>) occurred in animals given the highest dose. One late-appearing squamous cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> occurred in the vagina of a middle-dose animal. No vaginal tumors were found at the lowest dose.</p>
<p>In rats, 2Â late-appearing (after 20Â months), nonmetastasizing vaginal squamous cell carcinomas occurred in animals given the highest dose. No vaginal tumors occurred at the low or middle dose in rats. No other drug-related tumors were observed in either sex of either species.</p>
<p>At doses that produced tumors in mice and rats, the estimated drug exposure (as measured by AUC) was approximately 3Â times (mouse) and 24Â times (rat) the estimated human exposure at the recommended therapeutic dose of 100Â mg every 4Â hours.</p>
<p>It is not known how predictive the results of rodent carcinogenicity studies may be for humans.</p>
<p><span class="Underline">Mutagenicity:</span><span class="Italics"> Lamivudine: </span>Lamivudine was mutagenic in an L5178Y/TK<span class="Sup">+/-</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and clastogenic in a cytogenetic assay using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Lamivudine was negative in a microbial mutagenicity assay, in an inÂ vitro cell transformation assay, in a rat micronucleus test, in a rat bone marrow cytogenetic assay, and in an assay for unscheduled DNA synthesis in rat liver.</p>
<p><span class="Italics">Zidovudine: </span>Zidovudine was mutagenic in an L5178Y/TK<span class="Sup">+/-</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, positive in an inÂ vitro cell transformation assay, clastogenic in a cytogenetic assay using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and positive in mouse and rat micronucleus tests after repeated doses. It was negative in a cytogenetic study in rats given a single dose.</p>
<p><span class="Underline">Impairment of Fertility:</span><span class="Italics"> Lamivudine: </span>In a study of reproductive performance, lamivudine, administered to male and female rats at doses up to 130Â times the usual adult dose based on body surface area considerations, revealed no evidence of impaired fertility (judged by conception rates) and no effect on the survival, growth, and development to weaning of the offspring.</p>
<p><span class="Italics">Zidovudine:</span> Zidovudine, administered to male and female rats at doses up to 7Â times the usual adult dose based on body surface area considerations, had no effect on fertility judged by conception rates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3ecbfa92-dbda-4b86-862d-ffe9024aa285"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Reproductive and Developmental Toxicology Studies</h2>
<p class="First"><span class="Underline">Lamivudine:</span> Reproduction studies have been performed in rats and rabbits at orally administered doses up to 4,000Â mg/kg/day and 1,000Â mg/kg/day, respectively, producing plasma levels up to approximately 35Â times that for the adult HIV dose. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> due to lamivudine was observed. Evidence of early embryolethality was seen in the rabbit at exposure levels similar to those observed in humans, but there was no indication of this effect in the rat at exposure levels up to 35Â times those in humans. Studies in pregnant rats and rabbits showed that lamivudine is transferred to the fetus through the placenta.</p>
<p><span class="Underline">Zidovudine:</span> Oral teratology studies in the rat and in the rabbit at doses up to 500Â mg/kg/day revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> with zidovudine. Zidovudine treatment resulted in embryo/fetal toxicity as evidenced by an increase in the incidence of fetal resorptions in rats given 150 or 450Â mg/kg/day and rabbits given 500Â mg/kg/day. The doses used in the teratology studies resulted in peak zidovudine plasma concentrations (after one half of the daily dose) in rats 66 to 226Â times, and in rabbits 12 to 87Â times, mean steady-state peak human plasma concentrations (after one sixth of the daily dose) achieved with the recommended daily dose (100Â mg every 4Â hours). In an inÂ vitro experiment with fertilized mouse oocytes, zidovudine exposure resulted in a dose-dependent reduction in blastocyst formation. In an additional teratology study in rats, a dose of 3,000Â mg/kg/day (very near the oral median lethal dose in rats of 3,683Â mg/kg) caused marked maternal toxicity and an increase in the incidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. This dose resulted in peak zidovudine plasma concentrations 350Â times peak human plasma concentrations. (Estimated AUC in rats at this dose level was 300Â times the daily AUC in humans given 600Â mg/day.) No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was seen in this experiment at doses of 600Â mg/kg/day or less.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_814c8d07-fd70-415a-b2ec-2045cca8130e"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">There have been no clinical trials conducted with COMBIVIR. See <span class="Italics">Clinical Pharmacology (12.3)</span> for information about bioequivalence. One COMBIVIR Tablet given twice daily is an alternative regimen to EPIVIR Tablets 150Â mg twice daily plus RETROVIR 600Â mg per day in divided doses.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b89d5035-c3d3-4b24-b701-5292b3502fc5"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adults</h2>
<p class="First"><span class="Underline">Lamivudine Plus Zidovudine:</span> The NUCB3007 (CAESAR) study was conducted using EPIVIR 150-mg Tablets (150Â mg twice daily) and RETROVIR 100-mg Capsules (2 x 100Â mg 3 times daily). CAESAR was a multi-center, double-blind, placebo-controlled study comparing continued current therapy (zidovudine alone [62% of patients] or zidovudine with didanosine or zalcitabine [38% of patients]) to the addition of EPIVIR or EPIVIR plus an investigational non-nucleoside reverse transcriptase inhibitor, randomized 1:2:1. A total of 1,816Â HIV-1-infected adults with 25 to 250 (median 122) CD4Â cells/mm<span class="Sup">3</span> at baseline were enrolled: median age was 36Â years, 87% were male, 84% were nucleoside-experienced, and 16% were therapy-naive. The median duration on study was 12Â months. Results are summarized in TableÂ 5.</p>
<a name="id_d83ea1bf-769c-43a1-9bd2-f79a7ea08903"></a><table border="single" width="616.000">
<caption><span>Table 5. Number of Patients (%) With At Least 1 HIV-1 Disease-Progression Event or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></span></caption>
<col width="35.7%">
<col width="17.5%">
<col width="21.9%">
<col width="24.8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">Endpoint</td>
<td class="Botrule Rrule" align="center" valign="bottom">Current Therapy (nÂ =Â 460)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">EPIVIR </p>
<p>plus Current Therapy</p>(nÂ =Â 896)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">EPIVIR </p>
<p>plus a NNRTI<span class="Sup">a</span></p>plus Current Therapy (nÂ =Â 460)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">HIV-1 progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></td>
<td class="Rrule" align="center" valign="top">90 (19.6%)</td>
<td class="Rrule" align="center" valign="top">86 (9.6%)</td>
<td class="Rrule" align="center" valign="top">41 (8.9%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Botrule Rrule" align="center" valign="top">27 (5.9%)</td>
<td class="Botrule Rrule" align="center" valign="top">23 (2.6%)</td>
<td class="Botrule Rrule" align="center" valign="top">14 (3.0%)</td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top">
<span class="Sup">a</span> An investigational non-nucleoside reverse transcriptase inhibitor not approved in the United States.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bcfb408a-539e-4184-b42c-b41d07b38a16"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Prevention of Maternal-Fetal HIV-1 Transmission</h2>
<p class="First">The utility of zidovudine alone for the prevention of maternal-fetal HIV-1 transmission was demonstrated in a randomized, double-blind, placebo-controlled trial conducted in HIV-1-infected pregnant women with CD4+ cell counts of 200 to 1,818Â cells/mm<span class="Sup">3</span> (median in the treated group: 560Â cells/mm<span class="Sup">3</span>) who had little or no previous exposure to zidovudine. Oral zidovudine was initiated between 14 and 34Â weeks of gestation (median 11Â weeks of therapy) followed by IV administration of zidovudine during labor and delivery. Following birth, neonates received oral zidovudine syrup for 6Â weeks. The study showed a statistically significant difference in the incidence of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in the neonates (based on viral culture from peripheral blood) between the group receiving zidovudine and the group receiving placebo. Of 363Â neonates evaluated in the study, the estimated risk of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was 7.8% in the group receiving zidovudine and 24.9% in the placebo group, a relative reduction in transmission risk of 68.7%. Zidovudine was well tolerated by mothers and infants. There was no difference in pregnancy-related adverse events between the treatment groups.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_f6edcb3e-c4eb-4e71-9896-9568dedfab10"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">COMBIVIR Tablets, containing 150Â mg lamivudine and 300Â mg zidovudine, are white, scored, film-coated, modified-capsule-shaped tablets, debossed on both tablet faces, such that when broken in half, the full â€œGXFC3â€? code is present on both halves of the tablet (â€œGXâ€? on one face and â€œFC3â€? on the opposite face of the tablet). They are available as follows:</p>
<p>60 Tablets/Bottle (NDC 49702-202-18).</p>
<p>Unit Dose Pack of 120 (NDC 49702-202-29).</p>
<p><span class="Bold">Store between 2Â° and 30Â°C (36Â° and 86Â°F).</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_db717905-9942-4590-b7a9-1eddc8daeb3d"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f9471e7-f4f4-4a07-834b-9b746807f3e1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Advice for the Patient</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>:</span> Patients should be informed that the important toxicities associated with zidovudine are <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and/or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. They should be told of the extreme importance of having their blood counts followed closely while on therapy, especially for patients with advanced HIV-1 disease <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></span>: Patients should be informed that <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> with pathological changes, similar to that produced by HIV-1 disease, have been associated with prolonged use of zidovudine <span class="Italics">[see Warnings and Precautions (5.2)]</span>.Â  </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span>:</span> Patients should be informed that some HIV medicines, including COMBIVIR, can cause a rare, but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) <span class="Italics">[see Warnings and Precautions (5.3)]</span>.Â  </p>
<p>Â  <span class="Underline">HIV-1/HBV Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:</span> Patients co-infected with HIV-1 and HBV should be informed that deterioration of liver disease has occurred in some cases when treatment with lamivudine was discontinued. Patients should be advised to discuss any changes in regimen with their physician <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</p>
<p><span class="Underline"> Use With Other Lamivudine-, Zidovudine-, and/or Emtricitabine-Containing Products: </span>COMBIVIR should not be coadministered with drugs containing lamivudine, zidovudine, or emtricitabine, including EPIVIR (lamivudine), EPIVIR-HBV (lamivudine), RETROVIR (zidovudine), EPZICOM (abacavir sulfate and lamivudine), TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine), ATRIPLA (efavirenz, emtricitabine, and tenofovir), EMTRIVA (emtricitabine), TRUVADA (emtricitabine and tenofovir), or COMPLERA<span class="Sup">â„¢</span> (rilpivirine/emtricitabine/tenofovir) <span class="Italics">[see Warnings and Precautions (5.5)]. </span></p>
<p><span class="Underline">HIV-1/HCV Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span> Patients with HIV-1/HCV co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be informed that hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin <span class="Italics">[see Warnings and Precautions (5.6)]</span>.</p>
<p><span class="Italics">Â  </span><span class="Underline">Drug Interactions:</span> Patients should be cautioned about the use of other medications, including ganciclovir, interferon alfa, and ribavirin, which may exacerbate the toxicity of zidovudine <span class="Italics">[see Drug Interactions (7.3)]</span>.</p>
<p><span class="Underline">Redistribution/Accumulation of Body Fat:</span> Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time <span class="Italics">[see Warnings and Precautions (5.9)]</span>.</p>
<p><span class="Underline">Information About HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span> COMBIVIR is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should remain under the care of a physician when using COMBIVIR. </p>
<p> Patients should be advised to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<ul>
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom or other barrier method to lower the chance of sexual contact with semen, vaginal secretions, or blood. </li>
<li>
<span class="Bold">Do not breastfeed. </span>Lamivudine and zidovudine are excreted in human breast milk. Mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.Â  </li>
</ul>
<p> Patients should be informed to take all HIV medications exactly as prescribed. </p>
<p>EPIVIR, RETROVIR, EPZICOM, and TRIZIVIR are registered trademarks of ViiV Healthcare.</p>
<p>The other brands listed are trademarks of their respective owners and are not trademarks of ViiV Healthcare. The makers of these brands are not affiliated with and do not endorse ViiV Healthcare or its products.</p>
<p>Manufactured for:</p>
<p>ViiV Healthcare<br>Research Triangle Park, NC 27709</p>
<p>by GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Lamivudine is manufactured under agreement from<br><span class="Bold">Shire Pharmaceuticals Group plc<br></span>Basingstoke, UK</p>
<p>Â©2011, ViiV Healthcare. All rights reserved.</p>
<p>November 2011<br>CMB: 4PI</p>
<p>Repacked by:<br>H.J. Harkins Company, Inc.<br>513 Sandydale Drive<br>Nipomo, CA 93444</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_8127624a-c0c8-49ec-8f0b-b94e20bb6998"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p>NDC 49702-202-18 </p>
<p><span class="Bold">COMBIVIR<span class="Sup">Â®</span></span></p>
<p><span class="Bold"><span class="Italics">(lamivudine and zidovudine)</span></span></p>
<p><span class="Bold"><span class="Italics">Tablets 150 mg/300 mg</span></span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p><span class="Bold">60 Tablets</span></p>
<p>Each tablet contains 150 mg of lamivudine and 300 mg of zidovudine.</p>
<p>Store between 2<span class="Sup">o</span> and 30<span class="Sup">o</span>C (36<span class="Sup">o</span> and 86<span class="Sup">o</span>F).</p>
<p>See prescribing information for dosage information.</p>
<p>Do not use if printed safety seal under cap is broken or missing.</p>
<p>Manufactured for:</p>
<p>ViiV Healthcare</p>
<p>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Lamivudine is manufactured under agreement from</p>
<p><span class="Bold">Shire Pharmaceuticals Group plc</span></p>
<p>Basingstoke, UK</p>
<p>Made in UK</p>
<p>10000000082963 Rev. 8/10</p>
<p>Repacked by:<br>H.J. Harkins Company, Inc.<br>513 Sandydale Drive<br>Nipomo, CA 93444</p>
<div class="Figure"><img alt="COMBIVIR label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=479a2784-8db2-4fe5-94ba-55316a3c4e4f&amp;name=8fada68f-f4a9-4359-ba7d-d66c835da3a5-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>COMBIVIRÂ 		
					</strong><br><span class="contentTableReg">lamivudine and zidovudine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52959-546(NDC:49702-202)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LAMIVUDINE</strong> (LAMIVUDINE) </td>
<td class="formItem">LAMIVUDINE</td>
<td class="formItem">150Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ZIDOVUDINE</strong> (ZIDOVUDINE) </td>
<td class="formItem">ZIDOVUDINE</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (modified-capsule-shaped tablets) </td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GXFC3</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52959-546-02</td>
<td class="formItem">2  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:52959-546-03</td>
<td class="formItem">3  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:52959-546-04</td>
<td class="formItem">4  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:52959-546-06</td>
<td class="formItem">6  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:52959-546-08</td>
<td class="formItem">8  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:52959-546-10</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem">NDC:52959-546-14</td>
<td class="formItem">14  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">8</th>
<td class="formItem">NDC:52959-546-15</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">9</th>
<td class="formItem">NDC:52959-546-20</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">10</th>
<td class="formItem">NDC:52959-546-28</td>
<td class="formItem">28  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020857</td>
<td class="formItem">10/19/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>H.J. Harkins Company, Inc.
							(147681894)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>H.J. Harkins Company, Inc. (147681894)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">H.J. Harkins Company, Inc.</td>
<td class="formItem"></td>
<td class="formItem">147681894</td>
<td class="formItem">repack, relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>37641156-8d51-4e36-abb6-b46cb9e7f828</div>
<div>Set id: 479a2784-8db2-4fe5-94ba-55316a3c4e4f</div>
<div>Version: 1</div>
<div>Effective Time: 20120202</div>
</div>
</div>Â <div class="DistributorName">H.J. Harkins Company, Inc.</div></p>
</body></html>
